Western University

Scholarship@Western
Brain and Mind Institute Researchers'
Publications

Brain and Mind Institute

7-1-2021

Glutathione as a molecular marker of functional impairment in
patients with at-risk mental state: 7-tesla1H-MRS study
Peter Jeon
The University of Western Ontario

Roberto Limongi
Robarts Research Institute

Sabrina D. Ford
Robarts Research Institute

Cassandra Branco
The University of Western Ontario

Michael Mackinley
Robarts Research Institute

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/brainpub

Citation of this paper:
Jeon, Peter; Limongi, Roberto; Ford, Sabrina D.; Branco, Cassandra; Mackinley, Michael; Gupta, Maya;
Powe, Laura; Théberge, Jean; and Palaniyappan, Lena, "Glutathione as a molecular marker of functional
impairment in patients with at-risk mental state: 7-tesla1H-MRS study" (2021). Brain and Mind Institute
Researchers' Publications. 1023.
https://ir.lib.uwo.ca/brainpub/1023

Authors
Peter Jeon, Roberto Limongi, Sabrina D. Ford, Cassandra Branco, Michael Mackinley, Maya Gupta, Laura
Powe, Jean Théberge, and Lena Palaniyappan

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/brainpub/1023

brain
sciences
Article

Glutathione as a Molecular Marker of Functional Impairment
in Patients with At-Risk Mental State: 7-Tesla 1H-MRS Study
Peter Jeon 1,2 , Roberto Limongi 3 , Sabrina D. Ford 3,4 , Cassandra Branco 4 , Michael Mackinley 3,5 , Maya Gupta 6 ,
Laura Powe 4 , Jean Théberge 1,2,4,7,8 and Lena Palaniyappan 1,2,3,4, *
1

2
3

4

5
6
7
8

*



Citation: Jeon, P.; Limongi, R.; Ford,
S.D.; Branco, C.; Mackinley, M.;
Gupta, M.; Powe, L.; Théberge, J.;
Palaniyappan, L. Glutathione as a
Molecular Marker of Functional
Impairment in Patients with At-Risk
Mental State: 7-Tesla 1 H-MRS Study.
Brain Sci. 2021, 11, 941. https://
doi.org/10.3390/brainsci11070941
Academic Editor: Swapan K. Ray
Received: 6 April 2021

Department of Medical Biophysics, Western University, London, ON N6A 3K7, Canada; yjeon4@uwo.ca (P.J.);
jtheberge@lawsonimaging.ca (J.T.)
Lawson Health Research Institute, Imaging Division, London, ON N6A 4V2, Canada
Robarts Research Institute, Western University, London, ON N6A 3K7, Canada; rlimongi@uwo.ca (R.L.);
Sabrina.Ford@lhsc.on.ca (S.D.F.); Michael.MacKinley@lhsc.on.ca (M.M.)
Department of Psychiatry, Western University, London, ON N6A 3K7, Canada; cbranco3@uwo.ca (C.B.);
Laura.Powe@lhsc.on.ca (L.P.)
Department of Neuroscience, Western University, London, ON N6A 3K7, Canada
Department of Psychology, Western University, London, ON N6A 3K7, Canada; Maya.Gupta@lhsc.on.ca
St. Joseph’s Health Care, Diagnostic Imaging, London, ON N6A 4V2, Canada
Department of Medical Imaging, Western University, London, ON N6A 3K7, Canada
Correspondence: lpalaniy@uwo.ca; Tel.: +1-(519)-931-5777 (ext. 24398)

Abstract: A substantial number of individuals with clinical high-risk (CHR) mental state do not transition to psychosis. However, regardless of future diagnostic trajectories, many of these individuals
develop poor social and occupational functional outcomes. The levels of glutathione, a crucial cortical
antioxidant, may track variations in functional outcomes in early psychosis and prodromal states.
Thirteen clinical high-risk and 30 healthy control volunteers were recruited for a 7-Tesla magnetic
resonance spectroscopy scan with a voxel positioned within the dorsal anterior cingulate cortex
(ACC). Clinical assessment scores were collected to determine if any association was observable with
glutathione levels. The Bayesian Spearman’s test revealed a positive association between the Social
and Occupational Functioning Assessment Scale (SOFAS) and the glutathione concentration in the
clinical high-risk group but not in the healthy control group. After accounting for variations in the
SOFAS scores, the CHR group had higher GSH levels than the healthy subjects. This study is the
first to use 7-Tesla magnetic resonance spectroscopy to test whether ACC glutathione levels relate to
social and occupational functioning in a clinically high-risk group and offers preliminary support for
glutathione levels as a clinically actionable marker of prognosis in emerging adults presenting with
risk features for various severe mental illnesses.
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1. Introduction

iations.

Emerging adults with attenuated or brief and limited psychotic symptoms are said
to be in a clinical high-risk (CHR) state (or “at-risk or ultrahigh-risk” mental state) that
later develops into multiple diagnostic outcomes including schizophrenia, mood disorders,
such as bipolar disorder, or a major depressive disorder [1,2]. A substantial number of
individuals with CHR develop poor long-term functional (i.e., social and occupational)
outcomes irrespective of diagnostic transitions. Longitudinal studies indicate that a large
proportion of individuals with CHR do not transition to psychosis (65–89% not psychotic
over 2–10 years [3–5]) but have poor social and occupational outcomes (48% functionally
impaired at 3–10 years [3,6]). While functional outcomes improve over time in CHR
patients who have good functioning at the baseline, persistent deficits are seen in those
who start with lower levels of functioning [4]. In other words, lower levels of functioning
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in CHR state before the onset of diagnosable psychiatric disorders such as schizophrenia
and bipolar disorders reliably predict the trajectory of continued poor functioning over a
long time period. The molecular bases of such pervasive functional deficits continue to be
unknown [7], proving to be a major hurdle in developing meaningful treatments aimed at
CHR state.
Oxidative stress has emerged as a key mechanism underlying the pathophysiology of
many psychiatric disorders including psychosis [8]. Destructive free radicals that damage
brain tissue are by-products of oxidative metabolism but are effectively scavenged by
antioxidants. Glutathione (GSH), the cardinal antioxidant in brain cells, shows 27–52% reduction [9–11] in established schizophrenia. Genetic [12,13] and cell biology studies [14–16]
indicate that in a subset of patients, GSH production on demand is likely to be reduced [17].
We have recently demonstrated the prognostic importance of low GSH in predicting early
clinical response to antipsychotics in first-episode schizophrenia. In this study, we observed that for every 10% baseline difference in anterior cingulate cortex (ACC) GSH
among the patients, seven additional days of delay in response occurred after treatment
initiation [18]. Lack of early response is a critical indicator of long-term poor outcomes in
schizophrenia [19–21]. We and others have also related lower GSH to various determinants
of functional outcomes including residual symptom burden [22], negative symptoms [23]
and cognitive deficits [24], supporting the notion that the “hub of oxidative stress” indexed
by GSH [25,26] is likely a critical determinant of functioning.
To date, various imaging modalities have been employed to predict both conversion
to psychosis and functional outcomes in youth at CHR [27]. Structural MRI studies
report pronounced cortical thinning [28,29] and longitudinal reduction in gray matter
volume [30] in the ACC of CHR patients. These ACC abnormalities precede the psychosis
onset [28,31]. Furthermore, aberrant activation of ACC in fMRI studies using tasks that
demand executive controls has also been reported in CHR subjects who develop poor
symptomatic and functional outcomes [32–34]. While several other distributed structural
and functional changes precede and predict psychosis (see the review by Andreou and
Borgwardt [35]), a recent meta-analysis has established that dorsal ACC (dACC) is the only
brain region whose structural gray matter changes precede psychosis (i.e., in CHR state)
and persist even after long periods of treatment (i.e., in both acute and chronic stages) [36],
highlighting the crucial role of ACC for long-term outcomes.
We recently synthesized in vivo MRS studies on ACC and demonstrated a significant
GSH reduction in the established cases of schizophrenia but an elevation in bipolar disorders [37], indicating that GSH levels may track the variations in functional outcomes that
typify the prognostic course of psychiatric disorders. Such divergence between disorders
may mean that in the “pluripotent” CHR state that includes patients with varying levels
of functioning as a single group, GSH levels may not differ from healthy controls but
relate to variations in levels of functioning. In fact, in the only previous MRS study of
cortical glutathione in clinical high-risk state [38], da Silva et al. reported no difference
between healthy controls and CHR subjects in anterior cingulate glutathione [39]. Functional outcomes were not evaluated in this study; thus, the role of GSH as a transdiagnostic
prognostic marker in CHR state remains unknown.
In the current study, we use ultrahigh field 7T MRS for the first time to test if ACC
GSH levels relate to social and occupational functioning in the CHR group. We expected
GSH levels to be reduced among patients with poor functioning. Furthermore, we aimed at
establishing the difference in GSH levels between the CHR and healthy control subjects after
accounting for variations in functioning. We evaluated these hypotheses using Bayesian
and frequentist statistical approaches.
2. Materials and Methods
2.1. Participants
We recruited 13 clinical high-risk (CHR) volunteers along with 30 healthy control (HC)
volunteers group-matched for age, gender and parental socio-economic status. Patient
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volunteers were recruited from the referrals received by the PROSPECT (Prodromal Symptoms of Psychosis—Early Clinical Identification and Treatment) program at London Health
Sciences Center, London, Ontario. The patients were help-seeking individuals referred to
the clinic by community physicians, healthcare workers or friends/family. All the referrals
were reviewed by an intake coordinator via telephone using a validated instrument (PRIME
Screen—Revised). If found eligible for further assessment, the patients were evaluated
within 2 weeks of referral using the Structured Interview for Psychosis-risk Syndromes
(SIPS) [40]. Patients with medical conditions, pervasive developmental disorders or intellectual disability underlying the reported symptoms, those who received treatment
with antipsychotic medications to treat presenting symptoms (minimal effective dose for a
period of at least 2 weeks) and those with psychotic symptoms secondary to active substance use (intoxication effects) were excluded. Based on the SIPS, the patients satisfying
attenuated psychotic syndrome (APS) or brief and limited intermittent psychosis (BLIPS)
were both included in the CHR group. The healthy volunteers had no personal history
of mental illness with no family history of psychotic disorder. All the participants were
screened to exclude significant head injury, major medical illness or MRI contraindications
and provided written informed consent according to the guidelines of the Human Research
Ethics Board for Health Sciences at Western University, London, Ontario.
2.2. MRS Acquisition and Analysis
A Siemens MAGNETOM 7T head-only MRI scanner (Siemens, Erlangen, Germany)
was used for all MRS acquisition along with a site-built head coil (8-channel transmit,
32-channel receive coil array) at the Centre for Functional and Metabolic Mapping of
Western University (London, ON, Canada). A two-dimensional sagittal anatomical image
(37 slices, TR = 8000 ms, TE = 70 ms, flip-angle (α) = 120◦ , thickness = 3.5 mm, field of
view = 240 × 191 mm2 ) was used as reference to prescribe a 2.0 × 2.0 × 2.0 cm3 (8 cm3 )
1 H-MRS voxel on the bilateral dorsal ACC (Figure 1). The voxel position was prescribed
by setting the posterior face of the voxel to coincide with the precentral gyrus and setting
the position of the inferior face of the voxel to the most caudal point not part of the corpus
callosum. The voxel angle was set to be tangential to the corpus callosum. A semi-LASER
1 H-MRS sequence (TR = 7500 ms, TE = 100 ms, bandwidth = 6000 Hz, N = 2048) was
used to acquire 32 channel-combined, VAPOR [41] water-suppressed spectra as well as a
water-unsuppressed spectrum to be used for spectral editing and quantification. All the
participants were asked to fix their gaze on a white cross (50% gray background) during
MRS acquisition.
Using the techniques outlined by Near et al. [42], the 32 spectra were phase- and
frequency-corrected before being averaged into a single spectrum to be used for all subsequent analyses. QUECC [43] and HSVD [44] were applied to the spectrum for lineshape
deconvolution and removal of the residual water signal, respectively. Spectral fitting was
done using fitMAN [45], a time-domain fitting algorithm that uses a nonlinear iterative
Levenberg–Marquardt minimization algorithm to echo time-specific prior knowledge
templates. The metabolite fitting template included 17 brain metabolites: alanine, aspartate, choline, creatine, γ-aminobutyric acid (GABA), glucose, glutamate, glutamine,
glutathione, glycine, lactate, myo-inositol, N-acetylaspartate, N-acetylaspartylglutamate,
phosphorylethanolamine, scyllo-inositol and taurine. Due to the long echo time used, no
significant macromolecular contribution was expected. Metabolite quantification was then
performed using Barstool [46] with corrections made for tissue-specific (gray matter, white
matter, CSF) T1 and T2 relaxation through partial volume segmentation calculations of
voxels mapped onto T1 -weighted images acquired using a 0.75-mm isotropic MP2RAGE
sequence (TR = 6000 ms, TI1 = 800 ms, TI2 = 2700 ms, flip-angle 1 (α1 ) = 4◦ , flip-angle 2 (α2 )
= 5◦ , FOV = 350 mm × 263 mm × 350 mm, Tacq = 9 min 38 s, iPATPE = 3 and 6/8 partial
k-space). All spectral fit underwent visual quality inspection as well as the Cramer–Rao
lower bounds (CRLB) assessment for each metabolite.
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at the time of first presentation using the SOFAS [47] administered on the same day of
the scanning. To determine cannabis use in the previous six months, the Cannabis Abuse
Screening Test (CAST) was used [48]. The CAST is a six-item Likert-scale self-report
questionnaire which asks the participant about cannabis use and how it affects their daily
activities and relationships. Scores range from 6 to 30, with higher scores indicating
more cannabis use. To determine alcohol use in the previous 6 months, the Alcohol Use
Disorders Identification Test—Concise (AUDIT—C) [49] was used. The AUDIT—C is a
three-item Likert-scale self-report questionnaire which asks the participant about alcohol
use frequency and quantity. Scores range from 0 to 12, with higher scores indicating more
alcohol use. Alcohol users and nonusers were classified by AUDIT—C scores of four
or more and less than four, respectively. Lastly, nicotine use in the previous six months
was determined using the single-item Fagerström Test for Nicotine Dependence and the
smoking index [50]. The Fagerström test indicates time to the first cigarette after waking,
and the smoking index is calculated by multiplying the number of years regularly smoking
by the number of cigarettes per day divided by 20 cigarettes per pack. A lower Fagerström
test value indicates more nicotine dependence, and a higher smoking index indicates more
nicotine use. The 10-item Drug Abuse Screening Test (DAST-10) [51] was also employed for
substances other than cannabis, alcohol and nicotine, though our cohort did not endorse
any such use.
2.4. Bayesian Analysis
We evaluated the association between GSH and the SOFAS, the SOPS and the CAST
scores in the CHR group and the relationship between GSH and the SOFAS scores in
the HC group by using a Bayesian Spearman’s test [52]. This approach relies on data
augmentation via the Metropolis-within-Gibbs sampling algorithm. Briefly, we assumed
the rank data as the reflection of a latent (truncated) normal distribution which allowed us
to use a conventional likelihood function. That is to say, the latent continuous scores would
manifest as “degraded” rank values. Following this assumption, the data augmentation
algorithm would yield samples from a truncated posterior distribution. Here, we tested
the null hypothesis that ρ = 0 versus the alternative hypothesis that ρ ~ Uniform [−1,1]
(i.e., following a uniform prior distribution). We drew 11,000 samples using a Markov
chain Monte Carlo (MCMC) method using the “spearmanCorrelation.R” function in R as
specified by van Doorn et al. [52]. We reported the Bayes factor relative to the null model
(BF10 ). BF10 > 1.0 suggests evidence in support of the (alternative) hypothesis and vice
versa. We also reported the mode and the proportion of the posterior distribution (i.e.,
posterior proportion, PP) of the estimated ρ (rho) values differing from zero along with the
95% highest density interval of the most credible values (HDI).
We estimated the posterior distribution of the (estimated) between-groups differences
in the CAST, the AUDIT—C and the SOFAS scores by means of a generalized linear model
(GLM) within the context of hierarchical Bayesian parameter estimation as follows:
scoresi = β 0 +

∑

β group x group (i )

group

where the data conformed to normal distribution around the predicted value (score) with
(wide) data-scaled uniform prior distribution for the standard deviation (σi ). The baseline
parameter (β 0 ) had a data-scaled normal prior distribution with the mean equal to the
data mean and the (wide) standard deviation relative to the standard deviation (SDdata )
of the data (1/(SDdata × 5)2 ). Group deflection parameters (β group ) had normal prior
distributions with mean zero and gamma prior distribution for the standard deviation σβ
with data-scaled shape and rate parameters (SDdata /2 and 2 × SDdata , respectively). This
means that σβ provided informed priors on each group (deflection) parameter. In other
words, groups would act as priors between each other. In total, we estimated posterior
distributions of five free parameters (σi , β 0 , β HC , β CHR and σβ ). The posteriors were
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estimated in RJAGS using MCMC, drawing 11,000 samples (thinning = 10). We reported
the PP of the between-groups difference in scores.
To evaluate the group effect after accounting for the effect of the SOFAS scores, we
included those scores as a covariate in the GLM,

[ GSH ]i = β 0 +

∑

β group x group (i ) + β so f as xso f as (i )

group

in which we added a normal prior distribution of the covariate parameter ( β so f as ) which had
zero mean and the data-scaled standard deviation equal to 1/(2 × SDGSG_data/ SDSOFAS_data )2 .
In total, we estimated posterior distributions of six free parameters (σi , β 0 , β HC , β CHR , σβ
and β so f as ).
The posteriors were estimated in RJAGS using MCMC, drawing 11,000 samples
(thinning = 10). We reported the PP of the between-groups difference in GSH along with
the 95% HDI. The posterior distribution of the effect size of this difference is also reported.
There were two reasons for employing a Bayesian approach. First, we were interested in
recovering the whole posterior distribution of possible values of the parameters given the
data, constraining our discussion to the 95% highest density interval. Second, a Bayesian
approach allowed us to identify the support not only for the alternative hypothesis, but
also for the null hypothesis.
2.5. Frequentist Analysis
All frequentist statistical tests were computed using IBM SPSS Statistics version 26 [53].
Group demographic differences were calculated using t-tests and chi-squared tests for
continuous and dichotomous variables, respectively. Hierarchical regression was used
to assess the effect of the SOFAS scores and diagnosis (dummy coded CHR = 0, healthy
controls = 1), with parameter estimates examined to test individual variable effects. Lastly,
Spearman’s correlation was used to determine the correlation between metabolite levels
and clinical scores (SOFAS, CAST, AUDIT—C, SOPS).
3. Results
3.1. Demographic Data
Subject demographic and clinical data are summarized in Table 1. A small number
within the clinical high-risk group were being administered antidepressants (N = 3) or
benzodiazepine (N = 2) at the time of the scan. Mean percent CRLB values for CHR and
HC GSH were 10 ± 4% and 11 ± 4%, respectively. The CHR patients had substantially
high levels of functional impairment. The groups differed in the CAST scores, which
were higher in the CHR group than in the HC group (mode = 4.19, posterior proportion
(PP) = 1.0), but not in the AUDIT—C scores (mode = −0.01, PP = 0.6). The SOFAS scores
were higher in the HC group than in the CHR group (mode = 16.7, PP = 1.0).
3.2. GSH, CHR Status and Social and Occupational Functioning
The Spearman’s test revealed a positive association between the Social and Occupational Functioning Assessment Scale (SOFAS) scores and GSH in the CHR group (mode
ρ = 0.58, posterior proportion (PP) = 0.98, Bayesian factor in favor of H1 over null H0
(BF10 ) = 2.1), whereas in the HC, the test indicated “absence of association” (mode ρ = 0.11,
PP = 0.44, BF10 = 0.23). In the CHR group, there was neither an effect of the SOPS (mode
ρ = −0.17, PP = 0.78, BF10 = 0.22) nor an effect of the CAST (mode ρ = 0.32, PP = 0.87,
BF10 = 0.46) on GSH (Table 2). Note that most healthy controls reported no cannabis use,
leading to limited variance in the CAST scores that could not be meaningfully related
to GSH.

Brain Sci. 2021, 11, 941

7 of 13

Table 1. Demographics and clinical characteristics.
Characteristics

Clinical High Risk
(N = 13)

Healthy Controls
(N = 30)

t/χ2

p

Gender (male/female)
Marital status (Mar/S)
Age (M/SD)
Parental NS-SEC (M/SD)
Cannabis use (Y/N)
Antidepressant use (Y/N)
Benzodiazepine use (Y/N)
Antipsychotic use (Y/N)
SOPS, total (M/SD)
CAST, total (M/SD)
Audit—C, total (M/SD)
SOFAS (M/SD)
APS/BLIPS
Converted (Y/N)

11/2
1/12
22.2/4.0
3.54/0.88
6/7
3/10
2/11
1/12
8.4/5.0
11.4/7.8
5.5/3.8
67.7/9.5
13/0
3/10

19/11
2/28
21.8/3.7
3.03/1.38
1/29
6.2/0.8
5.9/2.5
82.7/3.8

1.948
0.009
−0.330
−1.444
4.926

0.163
0.926
0.745
0.158
0.026

−2.20
0.281
6.267

0.052
0.783
0.000

Chi-squared analyses for categorical variables and independent t-tests for continuous variables were used to
calculate p-values for differences between groups. Mar—married, S—single, M—mean, SD—standard deviation, NS-SEC—National Statistics Socio-economic Classification, Y—yes, N—no, SOPS—scale of prodromal
symptoms, CAST—Cannabis Abuse Screening Test, AUDIT—C—Alcohol Use Disorders Identification Test—
Concise, SOFAS—Social and Occupational Functioning Assessment Scale, APS—attenuated psychotic syndrome,
BLIPS—brief and limited intermittent psychosis.

Table 2. Parameter estimates (posteriors) of the hierarchical Bayesian linear model and the Spearman’s correlation test.
Parameter

Mean

Median

Mode

HDIlow

HDIhigh

β0
β[CHR]
β[HC]
βSOFAS
σβ
σi

0.849
0.135
−0.135
0.009
0.440
0.270
0.154
0.478
−0.073
0.201

0.842
0.135
−0.135
0.010
0.335
0.267
0.143
0.509
−0.076
0.207

0.823
0.135
−0.135
0.010
0.199
0.264
0.114
0.586
−0.171
0.315

−0.165
−0.013
−0.274
−0.004
0.000
0.212
−0126
0.045
−0.335
−0.124

1.875
0.274
0.013
0.023
1.155
0.332
0.378
0.769
0.196
0.500

ρ[HC]SOFAS
ρ[CHR]SOFAS
ρ[CHR]SOPS
ρ[CHR]CAST

Note: HDI represents 95% of the most credible values. HDI—highest density interval, β 0 —intercept, β[CHR] —
deflection parameter for the CHR group, β[HC] —deflection parameter for the HC group, βSOFAS —deflection
parameter for the SOFAS covariate, σβ —standard deviation of the baseline parameter, σi—standard deviation
of the predicted value, ρ[HC]SOFAS —Spearman’s correlation between the SOFAS score and GSH of the control
group, ρ[CHR]SOFAS —Spearman’s correlation between the SOFAS score and GSH of the CHR group, ρ[CHR]SOPS —
Spearman’s correlation between the SOPS score and GSH of the CHR group, ρ[CHR]CAST —Spearman’s correlation
between the CAST score and GSH of the CHR group.

After accounting for the SOFAS scores, the metabolite level in the HC group was
smaller than in the CHR group (mode difference = −0.27, PP = 0.97; effect size −1.06,
PP = 0.97). Summary statistics of the posterior distributions of the model’s parameter
estimates are reported in Table 2. Figure 2 shows the posterior distributions of the estimated
between-groups difference in GSH.
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Figure 3. Median split analysis of glutathione (GSH) on the SOFAS. (A) Mean (± SD) glutathione concentrations (mM) of
3. Median
of glutathione
on the
(A) Mean
(± SD)high-risk
glutathione
concentrations
(mM)
theFigure
low-GSH
(< 1.60 split
mM; analysis
N = 7) and
high-GSH (>(GSH)
1.60 mM;
N =SOFAS.
6) subgroups
of clinical
(CHR)
cohorts as well
as of
the low-GSH (< 1.60 mM; N = 7) and high-GSH (> 1.60 mM; N = 6) subgroups of clinical high-risk (CHR) cohorts as well as
of the healthy controls (HC; N = 30). (B) Mean (± SD) SOFAS scores of the same three groups. Asterisks denote significant
of the healthy controls (HC; N = 30). (B) Mean (± SD) SOFAS scores of the same three groups. Asterisks denote significant
differences between the groups based on one-way ANOVA with the Tukey’s multiple comparison test, with ** denoting
differences between the groups based on one-way ANOVA with the Tukey’s multiple comparison test, with ** denoting
p <p0.05
and
****
denoting
p <p 0.001.
< 0.05
and
****
denoting
< 0.001.

In a hierarchical regression model with the GSH level as the dependent variable,
In a hierarchical regression model with the GSH level as the dependent variable,
with
with the SOFAS score entered as a predictor for all the subjects, the adjusted
R2 of the
the SOFAS score entered as a predictor for all the subjects, the adjusted R2 of the model
model was −0.024, F(1, 41) = 0.013, p = 0.9, an insignificant effect. When the CHR status
was −0.024, F(1, 41) = 0.013, p = 0.9, an insignificant effect. When the CHR status was inwas included in the model, 2the R2 of the model increased to 0.07.2 This R2 increase was
cluded in the model, the R of the model increased to 0.07. This R increase was statistically
statistically significant, F(1, 40) = 5.18, p = 0.028. The regression coefficient for the CHR
significant, F(1, 40) = 5.18, p = 0.028. The regression coefficient for the CHR status was
status was significantly negative (B = −0.56, t = −2.28), indicating that the GSH level was
significantly negative (B = −0.56, t = −2.28), indicating that the GSH level was significantly
significantly higher in CHR subjects than in healthy controls after controlling for variance
higher in CHR subjects than in healthy controls after controlling for variance due to SOdue to SOFAS. In this model, the SOFAS had a trend level of significance as a predictor,
FAS. In this
the SOFAS
had
trendinlevel
of significance
as GSH
a predictor,
indicating
indicating
that model,
higher SOFAS
scores
area seen
the presence
of higher
levels (B
= 0.43,
that higher SOFAS scores are seen in the presence of higher GSH levels (B = 0.43, t = 1.75,
p = 0.09). These results are in keeping with the Bayesian analysis reported in the manuscript.

4. Discussion
Our data provide evidence in support of a relationship between GSH levels and so-
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t = 1.75, p = 0.09). These results are in keeping with the Bayesian analysis reported in
the manuscript.
4. Discussion
Our data provide evidence in support of a relationship between GSH levels and social
and occupational functioning in clinical high-risk state and the presence of higher GSH
in CHR subjects when the variance related to functional impairment is accounted for. In
this study, we observed no relationship between GSH levels in the ACC and the SOFAS in
the healthy volunteers, especially as the functional variability was within a narrow range
among the healthy subjects. Furthermore, we did not observe any correlations between
GSH and prodromal positive symptom severity. Taken together, these results support our
hypothesis that GSH is a key molecular substrate underlying the functional deficits seen in
the CHR state.
We report higher GSH after accounting for differences in functioning in CHR compared to healthy subjects, with reduced GSH being associated with reduced functioning
among the CHR subjects. In the presence of CHR, higher levels of GSH may occur as a compensatory process across the spectrum (thus leading to a group level increase in GSH), but
those who do not mount a sufficient GSH response may have poorer functional outcomes.
In healthy subjects, this compensatory drive does not occur. In line with our prior work
demonstrating the potentially counteracting effect of GSH on glutamatergic excitotoxicity
in early stages of psychosis [54,55], we only examined the dACC in this study. GSH levels
in the dACC also relate to core symptoms of psychosis such as disorganization [56], which
strongly predict poor outcomes when present in CHR [57]. Nevertheless, antioxidant
aberrations related to psychosis are unlikely to be limited only to the dACC, as striatal and
thalamic reductions of GSH were also demonstrated in prior MRS studies [24,58].
An exciting translational utility of identifying GSH deficit in low-functioning patients
is the therapeutic possibility of correcting it. A number of compounds with the potential to
correct the effects of GSH deficit are in the pipeline [59–61]. Of these, N-acetylcysteine has
been shown to improve cognition and negative symptoms in schizophrenia (six RCTs) [62]
and global functioning in mood disorders [63,64]. Given the persistent nature of functional
deficits, reversing them will likely require longer trials that are substantially difficult to
complete. Antioxidants that increase GSH levels are more likely to benefit patients whose
GSH levels are lower to begin with [65]. Our results support stratifying antioxidant trials
on the basis of the baseline functional impairment or GSH levels in the future.
Our study has a number of strengths. We used the 7T-MRS sequence with improved
specificity to detect GSH resonance with reduced macromolecular interference [18,66].
Among the MRS studies specifically optimized for GSH detection, 7T studies [22,67] report
higher effect sizes for GSH reduction in schizophrenia compared to 3T [12,68]. We also
recruited patients who had not been treated with antipsychotics and evaluated an age-,
gender- and parental socio-economic status-matched control group. Nevertheless, our
sample size was limited compared to the prior study addressing this issue using a 3T-MRS
sequence. Furthermore, we lacked the follow-up data necessary to identify transition to
psychosis among the CHR groups. From the published meta-analytical data, we expect
from one to three converters in the next 2–5 years of observation [69]. The final limitation
of our work was the imbalance of certain demographic characteristics, namely, CAST score
differences between groups and the imbalance of gender within the CHR group.
5. Conclusions
In summary, our data offer preliminary support for the GSH level as a clinically
actionable marker of prognosis in emerging adults presenting with risk features for various
severe mental illnesses. The use of a longitudinal approach to track GSH levels in future
CHR studies may help establish the mechanistic primacy of the antioxidant status in
determining long-term outcomes.
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